Restless Legs Syndrome (RLS) Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018

Overview

Restless legs syndrome (RLS) can be described as a neurological sleep disorder causing intense and irresistible urge in moving legs. It can either occur genetically or as a result of various medical problems such as Parkinson’s disease, iron deficiency, diabetes, peripheral neuropathy, and others. Symptoms of this disease include itching, aching, crawling, burning, throbbing, tingling, and creeping.

Although, there is no specific test developed to diagnose RLS. The symptoms can be treated by incorporating changes in lifestyle and behavior, followed by certain medications for sleeping, narcotic pain, iron treatment, seizures, and Parkinson’s disease. In addition, a number of approved therapeutic drugs are currently available in the market, including Neupro by UCB Biopharma SPRL, Horizant and Requip by GlaxoSmithKline plc, and Mirapex by Boehringer Ingelheim International GmbH. Moreover, a number of RLS therapeutic drug candidates are being developed in the pipeline.

In addition, positive clinical trial results and strategic decisions of companies to collaborate with other companies are also facilitating drug development in the pipeline. Additionally, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others.

Pipeline Analysis

As of March 2019, the RLS therapeutics pipeline comprises 10+ therapeutic candidates in different stages of development.

Epidemiology Analysis

The report provides epidemiology forecast of RLS for seven major markets, such as the U.S., Japan, and EU5 countries (the U.K., Germany, France, Italy, and Spain). It covers prevalent population and treated patient population for the period 2016–2028.

Competitive Landscape

UCB Biopharma SPRL, GlaxoSmithKline plc, NLS-1 Pharma AG, Bioprojet SCR, and Boehringer Ingelheim International GmbH are the key players involved in the development of RLS therapeutics.

Report Insights

Some highlights of the report, “Restless Legs Syndrome (RLS) Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019”, include:

• Detailed pipeline analysis of therapeutic candidates, which are being developed for the treatment of RLS, estimates and analyzes the emerging therapies and their progress status in different phases of development
• Comprehensive insights into pipeline phase products, with special focus on strategic development activities, inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, patents, and upcoming conferences
• Competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to RLS
• Epidemiology forecast of RLS for seven major markets (referred to as 7MM in the report), which include the U.S., Japan, and EU5 countries
• Analysis of marketed products for the treatment of RLS
• Detailed regulatory framework for drug approval in the U.S., Europe, and Japan.
• Key winning strategies of companies involved in the RLS therapeutic development, followed by Pharma Proff’s views

This report includes the restless leg syndrome pipeline analysis as of March 2018, to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, targets and mechanism of action, and drug origin with relevance to restless leg syndrome.

Restless Leg Syndrome Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company